hrd, rb-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in hr /her2- early bc
Published 1 year ago • 37 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
2:06
association of 80 gene signature reclassification with neoadjuvant treatment response in bc
-
7:15
characterizing the immune microenvironment before and following anti-her2 neoadjuvant therapy
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
2:17
loss of her2 after neoadjuvant treatment of her2 early bc
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
2:13
n9831 trial: genes associated with early and late recurrence in her2 breast cancer
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
2:32
neoadjuvant biomarker analysis of neorhea: palbociclib in er /her2- bc
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
1:17
perelisa: de-escalated therapy for hr /her2 bc with ki67 response following 2-week letrozole
-
1:35
gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
6:09
ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer
-
3:06
prognostic score in early hr /her2- breast cancer: rs, factors, mutations, histology
-
1:14
prognostic value of beta-2 adrenergic receptor levels in her2 breast cancer
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer
-
1:29
the predictive value of treatment response after neoadjuvant therapy